883231-23-0 Usage
Uses
Used in Pharmaceutical Synthesis:
Tert-Butyl (5-bromopyrimidin-2-yl)carbamate is used as an intermediate in the synthesis of pharmaceutical compounds for its ability to protect functional groups during chemical reactions. The steric hindrance provided by the tert-butyl group is advantageous in creating complex molecular structures with desired properties.
Used in Organic Chemistry:
In the field of organic chemistry, tert-Butyl (5-bromopyrimidin-2-yl)carbamate is used as a building block for constructing various organic molecules. Its structural features allow for the development of new compounds with potential applications in different areas of chemistry.
Used in Medicinal Chemistry and Drug Discovery:
Tert-Butyl (5-bromopyrimidin-2-yl)carbamate is employed as a key component in medicinal chemistry and drug discovery due to its structural versatility and the presence of biologically active groups. It can be incorporated into drug molecules to enhance their therapeutic effects and target specific biological pathways.
Used in Chemical Reactions with Steric Hindrance:
The tert-butyl group in tert-Butyl (5-bromopyrimidin-2-yl)carbamate is used to introduce steric hindrance in chemical reactions, which can be beneficial for controlling the reaction outcomes and protecting certain functional groups from unwanted side reactions.
Check Digit Verification of cas no
The CAS Registry Mumber 883231-23-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,3,2,3 and 1 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 883231-23:
(8*8)+(7*8)+(6*3)+(5*2)+(4*3)+(3*1)+(2*2)+(1*3)=170
170 % 10 = 0
So 883231-23-0 is a valid CAS Registry Number.
InChI:InChI=1/C9H12BrN3O2/c1-9(2,3)15-8(14)13-7-11-4-6(10)5-12-7/h4-5H,1-3H3,(H,11,12,13,14)
883231-23-0Relevant articles and documents
Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents
Peng, Wei,Tu, Zheng-Chao,Long, Zi-Jie,Liu, Quentin,Lu, Gui
, p. 644 - 654 (2015/12/31)
In this study, a series of novel 7 or 8-substituted 4-morpholine-quinazoline derivatives was designed and synthesized. Their PI3Kα inhibitory activities, antiproliferative activities against seven cancer cell lines, namely, PC-3, DU145, MCF-7, BT474, SK-BR-3, U937 and A431, were evaluated in vitro. Compound 17f proved to be a potential drug candidate with high PI3Kα inhibition activity (IC50 = 4.2 nM) and good antiproliferative activity. Compound 17f was also tested for its inhibitory activities against other kinases, such as PI3Kβ, PI3Kγ, PI3Kδ and mTOR, its effects on p-Akt (S473) and cell cycle. These results suggested that compound 17f could significantly inhibit the PI3K/Akt/mTOR pathway as a potent PI3K inhibitor and anticancer agent.
PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS
-
Page/Page column, (2014/04/18)
Process methods for making the dual mTOR/PI3K inhibitor GDC-0980, named as (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one, having the structure: and stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof.